Table 1. Baseline characteristics (a) and resource utilization and outcomes over 2 years (b) by country.

	France	Germany	Canada	UK	Ireland	Italy	The Netherlands	Venezuela	All	Difference (P-valuea)
(a)
Baseline characteristics (effectiveness analysis set)
n	398	420	188	410	49	365	350	47	2227
Age, year	77.5	76.7	79.8	77.7	72.7	75.2	77.2	73.1	76.9	<0.001
Female, %	61	60	61	60	73	58	63	60	61	0.626
Baseline VAS	56.0	52.9	47.2	55.0	64.7	65.5	50.1	48.3	55.4	<0.001
Lesion type, %										<0.001
No	2	3	2	0	4	1	2	2	2
Classic	29	19	10	17	55	27	19	38	22
Classic and occult	9	16	3	4	4	15	6	6	9
Occult	33	49	15	25	14	34	33	17	33
Disciform scar	0	1	2	0	8	0	1	0	1
Not available	27	12	69	54	14	23	39	36	34
Prior disease, %	92	95	93	92	88	95	92	98	93	0.140
Concomitant disease, %	87	90	86	95	92	93	86	74	90	<0.001
Health insurance, %										<0.001
Public	95	82	93	82	2	89	99	4	86
Private	2	17	1	1	94	0	1	53	7
No insurance	0	1	3	15	4	11	0	28	6
Not available	3	0	3	2	0	0	0	15	1
Reimbursement type, %b										<0.001
Individual	2	51	2	1	0	26	3	6	15
National standards	44	32	92	94	96	73	96	15	69
Separate contract	0	6	0	0	0	0	0	0	1
Independently	53	3	1	1	0	1	0	4	10
Patient	0	0	0	0	4	0	0	23	1
Not available	1	7	7	3	0	0	1	51	4
(b)
Resource allocation and outcomes in year 1 (first-year completers)
n	340	232	149	396	31	272	258	17	1695
Overall treatment duration, days	538.3	521.8	642.2	652.2	736.0	527.8	570.4	530.9	578.5	<0.001
Ranibizumab injections	4.6	4.8	6.8	5.9	7.4	4.0	6.8	3.4	5.4	<0.001
Treatment switch, %	1	14	15	1	6	10	3	41	6	0.632
Ophthalmoscopies	3.3	7.6	6.0	8.7	0.6	1.9	1.6	1.8	4.8	<0.001
Optical coherence tomography	5.7	2.9	2.8	9.3	6.2	3.3	4.1	2.5	5.2	<0.001
Fluorescein angiography	1.2	1.3	0.9	0.5	1.9	2.1	0.2	0.6	1.0	<0.001
ICGA	0.4	0.1	0	0.1	0	1.1	0	0	0.3	<0.001
Monitoring visitsc	3.9	3.9	1.3	4.3	1.7	5.3	2.4	4.9	3.7	<0.001
Clinic visitsc	4.9	5.1	7.7	6.2	8.1	4.2	7.1	3.8	5.8	<0.001
Vision gainer, %d	17	17	28	30	11	13	31	25	23	<0.001
Vision maintained, %d	65	66	76	77	71	61	71	58	70	0.001
Resource allocation and outcomes over 2 years (second-year completers)
N	240	136	107	350	18	159	163	11	1184
Overall treatment duration, days	620.1	628.1	729.0	692.1	855.6	651.9	672.5	635.7	667.4	<0.001
Ranibizumab injections	7.4	7.2	12.1	9.5	15.6	6.2	10.9	4.2	8.9	<0.001
Treatment switch, %	2	15	13	1	11	11	4	64	6	0.749
Ophthalmoscopies	6.1	12.4	11.6	15.6	0.8	3.8	2.8	3.3	9.2	<0.001
Optical coherence tomography	10.9	6.3	6.1	17.5	12.1	6.8	7.9	5.2	10.9	<0.001
Fluorescein angiography	1.9	2.2	1.1	0.6	3.2	3.7	0.2	1.1	1.5	<0.001
ICGA	0.7	0.2	0	0.1	0	2.2	0	0	0.5	<0.001
Monitoring visitsc	7.7	7.4	3.1	9.1	2.3	10.1	4.8	10.4	7.5	<0.001
Clinic visitsc	8.1	8.1	14.6	10.2	17.3	6.7	11.7	6.1	9.8	<0.001
Vision gainer, %d	21	21	31	28	20	14	33	38	25	0.004
Vision maintained, %d	64	57	62	76	67	54	75	50	67	<0.001

Abbreviations: ICGA, indocyanine green angiography; VAS, visual acuity score.

Mean unless stated.

^aP-value was derived from ANOVA test for continuous variables and χ² test for categorical variables.

^bIndividual: reimbursement granted individually for this patient and treatment occasion; national standards: reimbursement according to national standards; independently: reimbursement granted for patient independently of how often treatment was provided.

^cMonitoring (diagnostic assessments only) and clinic (scheduled treatment) visits. As this was an observational study, the actual number of treatments may differ to visits that were scheduled as clinic (treatment) visits, and the use of diagnostic tests, such as ophthalmoscopies, may have also occurred during clinic or monitoring visits, accounting for differences in numbers.

^dVision gainer (defined as patients who gained ⩾15 letters) and vision maintained (defined as no decline in visual acuity from baseline).